Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of Debio 4126 in previously SSA-treated acromegaly
MOH_2025-06-11_013991Phase 3Not yet recruiting
- Sponsor
- Debiopharm
- Start
- Mar 2025
- Modality
- Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Debio 4126 in acromegaly (3 arms), sponsored by Debiopharm. Primary endpoint: Primary endpoint not reported. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
Debio 4126
03
Conditions
acromegaly
Beyond the preview
Go deeper on MOH_2025-06-11_013991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-11_013991.